Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sunitinib Malate

FDA-approved product (capsule, oral), marketed as Sunitinib Malate, Sutent.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Sunitinib Malate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Clear cell renal carcinoma
  • Gastrointestinal stromal tumor
  • Neoplasm
  • Neuroendocrine neoplasm
  • Pancreatic neuroendocrine tumor
  • Papillary renal cell carcinoma
  • Renal cell adenocarcinoma
  • Renal cell carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sunitinib Malate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sunitinib Malate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer

    NCT00371553 · start 2006-11

    Registered record
    Registry ID
    NCT00371553
    Conditions
    Relapsed or Cisplatin-Refractory Germ Cell Cancer
    Interventions
    SU011248 (Sunitinib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-11
    Completion
    2009-06
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Cisplatin-Refractory Germ Cell Cancer
    InterventionSU011248 (Sunitinib)
    PhasePhase 2
    Registry statusCompleted

  • SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer

    NCT00270413 · start 2006-01

    Registered record
    Registry ID
    NCT00270413
    Conditions
    Metastatic Breast Cancer
    Interventions
    SU11248
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-01
    Completion
    2009-03
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionSU11248
    PhasePhase 2
    Registry statusCompleted

  • Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors

    NCT00511849 · start 2005-11

    Registered record
    Registry ID
    NCT00511849
    Conditions
    Neoplasms
    Interventions
    carboplatin + SU011248 (sunitinib) + paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-11
    Completion
    2009-02
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    Interventioncarboplatin + SU011248 (sunitinib) + paclitaxel
    PhasePhase 1
    Registry statusCompleted

  • Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

    NCT00712504 · start 2004-07

    Registered record
    Registry ID
    NCT00712504
    Conditions
    Advanced Solid Tumors; Non Small Cell Lung Cancer
    Interventions
    sunitinib; docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-07
    Completion
    2007-11
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors; Non Small Cell Lung Cancer
    Interventionsunitinib; docetaxel
    PhasePhase 1
    Registry statusCompleted

  • Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45

    NCT00914043

    Registered record
    Registry ID
    NCT00914043
    Conditions
    Breast Cancer; Fatigue
    Interventions
    gene expression analysis; microarray analysis; polymerase chain reaction; polymorphism analysis; reverse transcriptase-polymerase chain reaction; biologic sample preservation procedure; enzyme-linked immunosorbent assay; laboratory biomarker analysis; fatigue assessment and management
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    2010-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Fatigue
    Interventiongene expression analysis; microarray analysis; polymerase chain reaction; polymorphism analysis +5 more
    PhaseNot recorded
    Registry statusWithdrawn